Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Predictors of Outcome in Patients with Advanced Nonseminomatous Germ Cell Testicular Tumors

  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Predictor factors determining complete response to treatment are still not clearly defined. We aimed to evaluate clinicopathological features, risk factors, treatment responses, and survival analysis of patient with advanced nonseminomatous GCTs (NSGCTs). Materials and Methods: Between November 1999 and September 2011, 140 patients with stage II and III NSGCTs were referred to our institutions and 125 patients with complete clinical data were included in this retrospective study. Four cycles of BEP regimen were applied as a first-line treatment. Salvage chemotherapy and/or high-dose chemotherapy (HDCT) with autologous stem cell transplantation were given in patients who progressed after BEP chemotherapy. Post-chemotherapy surgery was performed in selected patients with incomplete radiographic response and normal tumor markers. Results: The median age was 28 years. For the good, intermediate and poor risk groups, compete response rates (CRR) were, 84.6%, 67.9% and 59.4%, respectively. Extragonadal tumors, stage 3 disease, intermediate and poor risk factors, rete testis invasion were associated with worse outcomes. There were 32 patients (25.6%) with non-CR who were treated with salvage treatment. Thirty-one patients died from GCTs and 94% of them had stage III disease. Conclusions: Even though response rates are high, some patients with GCTs still need salvage treatment and cure cannot be achieved. Non-complete response to platinium-based first-line treatment is a negative prognostic factor. Our study confirmed the need for a prognostic and predictive model and more effective salvage approaches.

Keywords

References

  1. Aass N, Klepp O, Cavallin-Stahl E, Dahl O, Wicklund H, et al (1991). Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol, 9, 818-26.
  2. Ataergin S, Ozet A, Arpaci F, et al (2007). Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center. Indian J Cancer, 44, 6-11. https://doi.org/10.4103/0019-509X.31161
  3. Beyer J, Albers P, Altena R, et al (2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol, 24, 878-88. https://doi.org/10.1093/annonc/mds579
  4. Daugaard G, Skoneczna I, Aass N, et al (2011). A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol, 22, 1054-61. https://doi.org/10.1093/annonc/mdq575
  5. de Wit R, Stoter G, Sleijfer DT, et al (1998). Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer, 78, 828-32. https://doi.org/10.1038/bjc.1998.587
  6. Devesa SS, Blot WJ, Stone BJ, et al (1995). Recent cancer trends in the United States. J Natl Cancer Inst, 87, 175-82. https://doi.org/10.1093/jnci/87.3.175
  7. Droz JP, Kramar A, Biron P, et al (2007). Genito-Urinary Group of the French Federation of Cancer. Failure of high-dose cyclophosphamide and etoposide combined with doubledose cisplatin and bone marrow support in patients with highvolume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol, 51, 739-746. https://doi.org/10.1016/j.eururo.2006.10.035
  8. Droz JP, Kramar A, Ghosn M, et al (1988). Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer, 62, 564-8. https://doi.org/10.1002/1097-0142(19880801)62:3<564::AID-CNCR2820620321>3.0.CO;2-A
  9. Edge SB BD, Compton CC (2010). AJCC Cancer Staging Manual. New York, NY: Springer.
  10. Einhorn LH, Donohue J.(1977). Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med, 87, 293-8. https://doi.org/10.7326/0003-4819-87-3-293
  11. Hanson PR, Belitsky P, Millard OH, Lannon SG. (1993). Prognostic factors in metastatic nonseminomatous germ cell tumours. Can J Surg, 36, 537-40.
  12. Hartmann JT, Nichols CR, Droz JP, et al (2002). Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. [Multicenter Study]. Ann Oncol, 13, 1017-28. https://doi.org/10.1093/annonc/mdf176
  13. Horwich A, Sleijfer DT, Fossa SD, et al (1997). Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in goodprognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Tria. J Clin Oncol, 15, 1844-52.
  14. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group (1997). J Clin Oncol, 15, 594-603.
  15. Javadpour N, Young JD, (1986). Prognostic factors in nonseminomatous testicular cancer. J Urol, 135, 497-499.
  16. Kamba T, Kamoto T, Okubo K, et al (2010). Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients. Int J Urol, 17, 980-7. https://doi.org/10.1111/j.1442-2042.2010.02645.x
  17. Kaye SB, Mead GM, Fossa S, et al (1998). Intensive inductionsequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol, 16, 692-701.
  18. Keskin S, Ekenel M, Basaran M, Bavbek S (2012). Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy. [Comparative Study]. Am J Clin Oncol, 35, 369-72. https://doi.org/10.1097/COC.0b013e3182155370
  19. Kollmannsberger C, Nichols C, Meisner C, et al (2000). Identification of prognostic subgroups among patients with metastatic ‘IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol, 11, 1115-20. https://doi.org/10.1023/A:1008333229936
  20. Krege S, Beyer J, Souchon R, et al (2008). European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol, 53, 497-513. https://doi.org/10.1016/j.eururo.2007.12.025
  21. Mazumdar M, Bajorin DF, Bacik J, et al (2001). Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol, 19, 2534-41.
  22. Motzer RJ, Agarwal N, Beard C, et al (2012). National Comprehensive Cancer, N. Testicular cancer. [Practice Guideline]. J Natl Compr Canc Netw, 10, 502-35.
  23. Motzer RJ, Nichols CJ, Margolin KA, et al (2007). Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol, 25, 247-56. https://doi.org/10.1200/JCO.2005.05.4528
  24. Nichols CR, Williams SD, Loehrer PJ, et al (1991). Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol, 9, 1163-72.
  25. Pohar KS, Rabbani F, Bosl GJ, et al (2003). Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol, 170, 1155-8. https://doi.org/10.1097/01.ju.0000087796.63505.70
  26. Schmoll HJ, Beyer J (1998). Prognostic factors in metastatic germ cell tumors. [Review]. Semin Oncol, 25, 174-85.
  27. Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  28. Stoter G, Sylvester R, Sleijfer DT, et al (1987). Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. Cancer Res, 47, 2714-8.
  29. Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, et al (2000). Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer. J Clin Oncol, 18, 358-62.
  30. van Dijk MR, Steyerberg EW, Stenning SP, Dusseldorp E, Habbema JD (2004). Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer, 90, 1176-83. https://doi.org/10.1038/sj.bjc.6601665
  31. Vogt AP, Chen Z, Osunkoya AO. (2010). Rete testis invasion by malignant germ cell tumor and/or intratubular germ cell neoplasia: what is the significance of this finding? Hum Pathol, 41, 1339-44. https://doi.org/10.1016/j.humpath.2010.03.005
  32. Warde P, Specht L, Horwich A, et al (2002). Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. [Meta-Analysis]. J Clin Oncol, 20, 4448-52. https://doi.org/10.1200/JCO.2002.01.038
  33. Williams SB, Kacker R, Winston D, et al (2011). Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer. J Urol, 186, 2245-8. https://doi.org/10.1016/j.juro.2011.07.101
  34. Williams SD, Birch R, Einhorn LH, et al (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med, 316, 1435-40. https://doi.org/10.1056/NEJM198706043162302

Cited by

  1. Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3525
  2. Knowledge, Attitude and Practices of Technicians Working at Hospitals Towards Testicular Cancer and Self-examination of Testicles in Turkey vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10095
  3. T Cells after Allogeneic Hematopoietic Stem Cell Transplantation and its Correlation with Invasive Fungal Infection in Patients with Hematological Malignancies vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3137